At the time of writing, Viking Therapeutics Inc [VKTX] stock is trading at $34.07, up 7.71%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VKTX shares have gain 15.49% over the last week, with a monthly amount glided 0.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Viking Therapeutics Inc [NASDAQ: VKTX] stock has seen the most recent analyst activity on February 13, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $102. Previously, Citigroup started tracking the stock with Neutral rating on February 07, 2025, and set its price target to $38. On December 02, 2024, Piper Sandler initiated with a Overweight rating. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $109 on November 22, 2024. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $102 on November 04, 2024. JP Morgan started tracking with a Overweight rating for this stock on September 11, 2024, and assigned it a price target of $80. In a note dated June 27, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $105 on this stock.
For the past year, the stock price of Viking Therapeutics Inc fluctuated between $28.64 and $99.41. Currently, Wall Street analysts expect the stock to reach $98 within the next 12 months. Viking Therapeutics Inc [NASDAQ: VKTX] shares were valued at $34.07 at the most recent close of the market. An investor can expect a potential return of 187.64% based on the average VKTX price forecast.
Analyzing the VKTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.29% with Operating Profit Margin at -307.27%, Pretax Profit Margin comes in at -227.41%, and Net Profit Margin reading is -227.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.13 and Total Capital is -0.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.58 points at the first support level, and at 29.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.47, and for the 2nd resistance point, it is at 38.88.
Ratios To Look Out For
It is important to note that Viking Therapeutics Inc [NASDAQ:VKTX] has a current ratio of 33.09. Further, the Quick Ratio stands at 36.47, while the Cash Ratio is 1.96.
Transactions by insiders
Recent insider trading involved Lian Brian, President & CEO, that happened on Jan 06 ’25 when 0.19 million shares were sold. Chief Operating Officer, Mancini Marianna completed a deal on Jan 06 ’25 to sell 54215.0 shares. Meanwhile, Chief Financial Officer ZANTE GREG sold 50309.0 shares on Jan 06 ’25.
